GlassScriptPhysician profile
Paul W Mcmullan
NPI 1447204961
$3,179.95
in general payments reported to CMS, 2019-2025
19 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.85 · 2021: $161 · 2022: $984 · 2023: $1,108 · 2024: $693 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,946.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $672.87 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, 2nd Gen Centrimag Primary Console |
| Inari Medical, INC. | $654.77 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abiomed | $413.27 | 2021-2023 | Impella |
| Boston Scientific Corporation | $399.12 | 2019-2023 | Watchman Flx, Watchman Access System |
| Amgen INC. | $194.35 | 2022-2024 | Repatha |
| Siemens Medical Solutions USA, INC. | $160.65 | 2023 | Biograph Horizon-3r |
| Janssen Pharmaceuticals, INC | $151.76 | 2022-2024 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $130.21 | 2024 | Arcalyst |
| Heartflow, INC. | $123.78 | 2024 | |
| Pfizer INC. | $66.43 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $42.02 | 2024-2025 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.18 | 2019-2023 | Lifevest |
| Novartis Pharmaceuticals Corporation | $33.19 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $25.53 | 2022 | |
| Recor Medical INC | $22.32 | 2024 | Paradise Renal Denervation System |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.51 | 2019 | |
| Scpharmaceuticals INC. | $13.54 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Penumbra, INC. | $10.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Mcmullan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.